Investigational drug · Phase 3
TAK-755
Also called: rADAMTS13, recombinant ADAMTS13, SHP-655, BAX 930
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Thrombotic Thrombocytopenic Purpura (TTP), Acute Ischemic Stroke.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
7
Any phase or sponsor naming "TAK-755"
First trial start
2021
Apr 14, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TAK-755", any sponsor or status.
Conditions studied
As listed on its trial records.
- Thrombotic Thrombocytopenic Purpura (TTP)
- Acute Ischemic Stroke
Approved drugs for the same conditions: Stroke prevention · Hematology and blood cancers · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "TAK-755" as an intervention, largest first.
- A Study of TAK-755 in Adults With Acute Ischemic StrokePivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07392450 · 222 participants (planned) · Start May 17, 2026 · Primary completion Dec 6, 2027
Drug: TAK-755 · For: Acute Ischemic Stroke
Sites: Scottsdale, Arizona; Tucson, Arizona; San Francisco, California · 60 sites in all
- A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic PurpuraPivotal-lookingActive, not recruiting
TakedaTakeda (TAK)
NCT04683003 · 77 participants (planned) · Start Apr 14, 2021 · Primary completion Mar 16, 2027
Drug: TAK-755 · For: Thrombotic Thrombocytopenic Purpura (TTP)
Sites: Atlanta, Georgia; Buffalo, New York; Durham, North Carolina · 27 sites in all
- A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)Pivotal-lookingCompleted
Baxalta now part of ShireTakeda (TAK)
NCT03393975 · 52 participants · Start Oct 13, 2017 · Primary completion Dec 28, 2023
Drug: TAK-755; Standard of care · For: Thrombotic Thrombocytopenic Purpura (TTP)
Sites: Atlanta, Georgia; Las Vegas, Nevada; Durham, North Carolina · 33 sites in all
- A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic PurpuraRecruiting
TakedaTakeda (TAK)
NCT06441578 · 40 participants (planned) · Start May 30, 2024 · Primary completion Sep 30, 2032
Drug: Recombinant ADAMTS13 · For: Thrombotic Thrombocytopenic Purpura (TTP)
Sites: Tokyo, Japan
TakedaTakeda (TAK)
NCT05714969 · 29 participants · Start Jul 21, 2023 · Primary completion Apr 16, 2026
Drug: TAK-755 · For: Thrombotic Thrombocytopenic Purpura (TTP)
Sites: Gainesville, Florida; Boston, Massachusetts; Minneapolis, Minnesota · 22 sites in all
ShireTakeda (TAK)
NCT03997760 · 19 participants · Start Oct 21, 2019 · Primary completion Oct 26, 2022
Drug: TAK-755 · For: Sickle Cell Disease
Sites: Birmingham, Alabama; Little Rock, Arkansas; Aurora, Colorado · 14 sites in all
- Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)Approved for marketing
TakedaTakeda (TAK)
NCT05770219
Drug: TAK-755 · For: Thrombotic Thrombocytopenic Purpura (TTP)
Newest research
PubMed records naming it or its code names, newest first.
- ADAMTS13 at 25: From the mystery of thrombotic thrombocytopenic purpura to the molecular paradigm of mechanoregulated proteolysis.
George O, Momanyi TO, Miranda FZ, et al. · Thromb Update 2026
- Clinical Practice Guideline: The Diagnosis, Treatment, and Follow-Up Management of Thrombotic Thrombocytopenic Purpura.
Wendt R, Bommer M, Tiebel O, et al. · Dtsch Arztebl Int 2026
- Long-Term Real-World Effectiveness and Safety of Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura: A Multicenter Retrospective Follow-Up Study in Poland.
Laguna A, Szczepanska M, Pietrys D, et al. · Cureus 2026
- Recombinant ADAMTS13 Ameliorates Liver Injury and Improves Hepatic Microcirculation in a Murine Acute-on-Chronic Liver Failure Model.
Hanatani JI, Nishimura N, Kaji K, et al. · Hepatol Res 2026
- Glycosylation and Immunogenicity in Recombinant Proteins Acting on the FVIII/VWF-ADAMTS13 Axis.
Sakurai Y, Fujimura Y, Sakai K, et al. · Thromb Haemost 2026
- The role of VWF/ADAMTS13 axis in COVID-19-associated coagulopathy.
Zhang Q, Tan Y, Peng M, et al. · Front Cardiovasc Med 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Takeda.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.